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Pulmonary arterial hypertension is an important complication of systemic sclerosis with high 
mortality but should be regarded as a treatable manifestation of the disease.  Management 
draws on experience from other forms of pulmonary arterial hypertension and benefits 
from an increasing number of licensed therapies.  Outcome is variable but recent clinical 
trials suggest that combination therapies used early in the disease may be associated with 
better outcome.  This is important because previous clinical trials using short term gain in 
exercise capacity did not show significant benefit compared to that observed for idiopathic 
or heritable forms of PAH.  Thus, it is important to identify cases as early as possible and to 
manage cases that are in a high-risk group using early combination therapy.  This review 
summarises the most recent analyses of clinical trial data, with a focus on those patients 
with SSc associated PAH and provides the evidence base that supports current treatment 
recommendations for aggressive PAH occurring in systemic sclerosis, including the early use 







Long-term event-driven clinical trials for patients with WHO Group I pulmonary 
hypertension (PAH) have demonstrated benefits of targeted vasodilator therapies, including 
a substantial proportion of cases in which different PAH specific drugs were used in 
combination.  They have also re-affirmed the treatment effects that occur for key subtypes 
of PAH, especially that associated with connective tissue disease (PAH-CTD) and systemic 
sclerosis (PAH-SSc).   The recent Ambition trial has demonstrated the efficacy of upfront 
combination therapy in delaying clinical failure among patients with pulmonary arterial 
hypertension (PAH)1.  An identical efficacy to that observed in idiopathic PAH (IPAH) with 
confidence intervals below unity is evident in the subgroup of patients with systemic 
sclerosis (SSc)2. In isolation, as a post-hoc analysis of a very carefully selected population 
one might not get too excited about this observation, however similar findings in the 
GRIPHON trial3 and the SERAPHIN trial4 provide grounds for asserting that there is a genuine 
effect being observed here. Further there is published data demonstrating the mechanism 
of benefit5, with a much greater haemodynamic response and improve right ventricular 
function using upfront combination therapy in the SSc population. The consequence is quite 
profound, given the misgivings that have been expressed in respect of the value of treating 
patients with CTD including those with scleroderma6. To explore the magnitude of the shift 
in perspectives required, we shall set out the background reasons for concern in respect of 
PAH-SSC and explore the ‘explanations proposed, dissect the recent ‘outcome’ trials, and 
finally consider not just the aggression of therapy in terms of intensity, but also timing. 
 
PAH-SSc ‘a challenging subgroup’. 
While patients with SSc have a similar histological basis for PAH7 and the initial open label 
randomised trial suggested a high level of effort response in a short-term trial8, subsequent 
short-term trials were disappointing9, as the treatment effect in terms of the primary 
endpoint (6MWD) appeared consistently inferior to that of the IPAH population. The only 
meta-analysis using individual patient data confirmed attenuated benefit in the PAH-CTD 
population6 in terms of the primary endpoint in these trials (6MWD) and time to clinical 
worsening, while being associated with increased risk of adverse events (but not serious 
adverse events) in those exposed to active therapy10. The authors suggested that exclusion 
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of the PAH-CTD population might reduce the necessary study size and associated costs. 
Figure 1 shows that impact on 6MWD and clinical worsening from this meta-analysis, of 
note the impact on these endpoint is not significantly different between the IPAH and SSc 
sub-populations. The efficacy in the SSc population in terms of 6MWD persists after 
correction for comorbidities and background medications, driven by deterioration in the 
placebo group. However, the ‘apparent’ benefit in terms of clinical worsening becomes non-
significant unless the SERAPHIN trial is censored at 18 weeks, as shown below the 3mg 
dosing was ineffective in the CTD population and when all follow up is included this trial 
provides 72% of effect observed, thus potentially biasing the analysis. 
Proposed explanations for the limited improvement on therapy include the older age of 
SSc11 PAH patients, the prevalence of left heart12, lung disease13 and the higher prevalence 
of pulmonary veno-occlusive disease (PVOD)14. The negative results in older trials was 
counter-intuitive given the excellent clinical response seen in registries with substantial 
improvements in survival15,16. One very recent publication has suggested no progress in SSc 
survival in the past decade17, intriguingly this paper provides further support for the need 
for aggressive treatment of PAH-SSc patients, as maximal administered therapy (despite a 
50% 3-year mortality) was monotherapy in 40%, oral combination therapy in only 37% and 
prostanoid usage of any type was almost 50% less frequent in the PAH-SSc patients.  One 
thing is clear from the confusing data published on the PAH-SSc population, that a more 
rigorous approach to diagnosis is essential in this population.  To provide a secure diagnosis 
of “clean” (WHO Group I) PAH-SSc a rigorous assessment to exclude other forms of PH is 
needed.  We propose such an approach in Figure 2, recognising that most trials and 
registries have not mandated such rigour and so outcomes and analyses should take that 
into account. 
It is notable that the increased rate of adverse events in CTD patients in the meta-analysis, 
this was driven by GI bleeding and infections10.  The former may reflect the high use of 
anticoagulants in PAH-CTD patients (SSc being associated with angiodysplasia and gastric 
antral vascular ectasia) before recent16 showed that this did not improve outcomes in these 
patients and may well have been contributed to by drug-drug interactions with warfarin.  
Increased infection rate may reflect frequent use of corticosteroids and other 
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immunosuppression in non-SSc CTDs and so may not be as relevant to the PAH-SSc 
subgroup. 
 
Is co-morbid cardiopulmonary disease the reason for poor outcomes in trials? 
Lung fibrosis associated pulmonary hypertension (PH-SSc) has been reported as being 
associated with a particularly dismal prognosis18,19. Most trials do not require HRCT 
exclusion of lung disease, relying instead on spirometric assessment alone.  This allows 
patients with combined fibrosis and emphysema and a proportion of patients with 
significant fibrosis to be recruited. Fortunately, most expert centres use accepted criteria or 
Goh et al (2008) to exclude significant fibrosis when diagnosing SSc PAH, thus identifying 
significant emphysema and fibrosis before attributing the PH to vasculopathy. However, one 
must accept that with current inclusion and exclusion criteria, a proportion of patients with 
significant lung disease could contaminate the results for all populations recruited. From the 
UK national registry, we see that this could affect around 30% of patients diagnosed as 
having IPAH20 – a similar level to the prevalence of lung disease to that seen in SSc. One may 
conclude that parenchymal lung disease remains a confounder – but not especially so in the 
SSc subpopulation. 
Pulmonary hypertension associated with left heart disease has been reported as having a 
worse prognosis than PAH-SSc21 thus, underestimating the prevalence of post-capillary PH 
in studies could theoretically lead to a much worse outcome in SSc PH subgroups. Fox et al 
found that 2/3 of patients with PH-SSc had post-capillary PH12, most being identifiable by 
the presence of an elevated wedge pressure, but one in three being identified only on 
assessment of the left ventricular end diastolic pressure (14%) or unmasked on fluid 
challenge (17%). The reliability of fluid challenge in this setting remains to be established22, 
and the issues in respect of the haemodynamic definition of post-capillary PH in SSc are 
complex23.  In the AMBITION study, the modification of the recruitment criteria would have 
excluded most such patients, however recruitment in the GRIPHON & SERAPHIN studies 
used standard criteria. If this explanation were correct one would expect a different 




It is worth observing that in the study by Bourji et al21, the patients with left heart disease 
had higher mean pulmonary artery pressures than the PAH-SSc patients and despite 
elevated wedge pressures 75% were treated with advanced therapies, over half with ERAs. 
Thus, the poorer prognosis in this subgroup may have had many contributors. 
Gunther et al14 found that over 60% of SSc PAH patients had two or more CT features of 
PVOD and that this was associated with a 50% incidence of pulmonary oedema on therapy 
and early death. A high prevalence of PVOD as reported by Gunther et al could readily 
explain a poor response to therapy and higher SAE rate on therapy.  However, the 
population studied was highly selected (failed therapy referred for transplantation), and no 
other reports of a high prevalence of pulmonary oedema followed.  In an analysis of 66 
patients referred to our service, we observed only 11% with two or more features of PVOD 
and only 6% developed pulmonary oedema on therapy24 – insufficient to explain the 
apparent poor response to therapy reported. 
 
PAH-CTD in recent outcome trials 
The four recent large scale long-term outcome trials1,3,4,25 have reported almost identical 
benefit in the IPAH and PAH-CTD subgroups and unlike previous studies have tended to 
include a sufficiently large CTD population to allow subpopulation analysis. Table 1 shows 
the number of patients in IPAH groups, CTD and SSc in each of these trials and the 
proportion in the active therapy group on combination therapy. Figure 3 shows a Forest plot 
based on data abstracted from these studies and demonstrates the remarkable consistency 
between the IPAH (and various associated conditions according to study groupings) and CTD 
populations for the primary endpoint in these trials. In the Compass-2 trial bosentan and 
sildenafil was ineffective in both populations, possibly reflecting the drug- drug interaction 
between bosentan and sildenafil, though a high drop-out rate and significant proportion 
with possible left heart disease may also explain the outcome. For SERAPHIN 10mg; 
AMBITION and GRIPHON almost identical outcomes are evident. In the SERAPHIN study 64% 
of patients were on combination therapy, in GRIPHON 80%, while in the study treatment 
arm of the AMBITION trial 100% were on combination therapy.  Numerically superior 
efficacy in the CTD population is associated with the most aggressive of these regimes.  In 
7 
 
the 3mg arm of the SERAPHIN study, efficacy is evident in the IPAH arm but not the CTD 
arm, suggesting that less intense therapy is effective in the IPAH arm but not the CTD arm. 
 
The SSc population in the AMBITION Trial. 
The AMBITION trial1,2 was almost unique in the field of pulmonary hypertension, in that 
patients were enrolled ‘upfront’ prior to any therapy and randomised to ambrisentan and 
tadalafil initial combination therapy (ambrisentan 10 mg plus tadalafil 40 mg) or to 
ambrisentan 10mg (plus placebo) or tadalafil 40mg (plus placebo) monotherapy.  
Patients were aged 18 to 75 years, had baseline WHO functional class II or III symptoms and 
the average time from diagnosis to enrolment was only 22 days. Initial inclusion criteria 
required only standard haemodynamic criteria for precapillary PH and a total lung capacity 
≥60% of predicted normal, and forced expiratory volume in 1 second ≥55% of predicted 
normal.  After 6 months, a blinded review of the participants’ baseline demographic data 
revealed a high prevalence of risk factors for left ventricular diastolic dysfunction and a high 
drop-out rate among such patients. Therefore, the eligibility criteria were amended to 
include more rigorous haemodynamic requirements (PVR > 300dynes.seccm-5 if LVEDP or 
PCW < 12mmHg, PCW > 500 if PCW/LVEDP 12 – 15mmHg) and to exclude patients with ≥3 
risk factors for left ventricular diastolic dysfunction: body mass index ≥30 kg/m2, history of 
essential hypertension, diabetes mellitus, and historical evidence of significant coronary 
artery disease.  
Given these modified criteria, patients of advanced age and those likely to have cardiac co-
morbidity are excluded from the main analysis. Potentially this selects for a more favourable 
treatment cohort, where a more ‘vascular’ profile is expected. However, when comparing to 
registry populations as shown in Table 2, the resultant study population is quite typical – 
slightly younger and less symptomatic, but very similar in terms of pulmonary and 
haemodynamic parameters. 
 
Results of the AMBITION trial 
The results of the AMBITION trial are quite striking.  They suggest that with an aggressive 
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upfront approach, equivalent outcomes are achievable in PAH-SSc and IPAH/HPAH as shown 
in Table 3.  The primary endpoint was time to clinical failure – a composite endpoint 
comprising defined as the first occurrence of death, hospitalisation for worsening PAH (any 
hospitalisation for worsening PAH, lung or heart/lung transplant, atrial septostomy or 
initiation of parenteral prostanoid therapy), disease progression (decrease of >15% from 
baseline 6MWD combined with WHO functional class III or IV symptoms at two consecutive 
visits separated by ≥14 days) or unsatisfactory long-term clinical response (any decrease 
from baseline 6MWD at two consecutive post-baseline clinic visits separated by ≥14 days 
and WHO functional class III symptoms assessed at two clinic visits separated by ≥6 
months).  
The primary endpoint occurred in 32% of IPAH/HPAH patients and 40% of PAH-SSc patients 
receiving monotherapy. By contrast in the initial combination therapy group the primary 
endpoint occurred in 19% of the IPAH/HPAH patients (a 49% reduction) and 21% of SScPAH 
patients (a 56% reduction).  Thus, with an upfront aggressive strategy there is much less 
difference in outcomes between IPAH/HPAH and PAH-SSc than in previous trials. 
In those receiving initial combination therapy (Table 3), the likelihood of hospitalisation for 
PAH, improvement in six-minute walking distance and reduction in NTproBNP was very 
similar to the effect of combination therapy in the IPAH/HPAH groups. The impact in terms 
of improvement in 6MWD is particularly striking.  In this study, it was not deterioration in 
6MWD in the placebo group (who received monotherapy) but rather an impressive positive 
response to combination therapy that delivered the treatment effect.  By contrast there was 
a trend toward fewer achieving a satisfactory clinical outcome. Although discontinuation 
rates resulting from adverse events was higher in the PAH-SSc population, neither AE 
related discontinuation rates nor SAE rates were increased by combination therapy when 
compared to monotherapy (Table 3).  Comparing the secondary endpoint outcomes in the 
monotherapy arms between the SSc and IPAH/HPAH populations it is notable that 
monotherapy appears less effective in the SSc population in terms of 6MWD (+12 v + 26 m), 
reduction in N-TproBNP (-38% v – 42%) and 15% fall in 6MWD (44% v 32%), however the 
magnitude of improvement in each of these in the combination group relative to the 
monotherapy arms is just as great. Thus, there is a synergistic effect of combination therapy 
in the SSc subgroup.  The suggestion therefore from this analysis is that in the PAH-SSc 
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population a similar medium-term outcome to IPAH/HPAH can be achieved with a 
sufficiently aggressive therapeutic approach. There is however a residual note of caution 
that the degree of improvement is more likely to be insufficient to attain a satisfactory 
clinical outcome in nearly 70% of patients. 
 
Mechanistic basis for efficacy of upfront combination therapy in PAH-SSc 
Hassoun et al5 evaluated 24 patients with PAH-SSc that received upfront ambrisentan and 
Tadalafil following the AMBITION protocol. The co-primary endpoints were change in PVR 
and reduction in RV mass at 36 weeks, both were significant.  Upfront combination therapy 
reduced mPAP from 42+ 12 to 30+ 7 mmHg, increased cardiac index from 2.6+0.7 to 3.3+1.2 
l.min/m2 a significantly greater haemodynamic improvement that recorded in previous 
monotherapy trials in this population. 
As observed in the AMBITION trial 6MWD increased significantly from 343+131 to 395+ 
99m. Further a clear improvement in right ventricular function was observed right 
ventricular ejection fraction improved from 46+10 to 57+ 9%, while right ventricular end 
systolic volume fell from 82.1 (65.6–97.7) to 55.8 (49.4–79.2) and left ventricular end 
diastolic volume increased from 114.0 (84.8–130.2) to 135.3 (112.4–160.1).  All these 
changes reach significance and indicate substantial off-loading with upfront combination 
therapy, with improved RV function and LV filling.  This was an open-label trial with per-
protocol analysis, that said of the 17 patients excluded before treatment 12 met exclusion 
criteria, and only one patient was subsequently excluded as they elected to have palliation. 
 
The GRIPHON trial 
The GRIPHON3 is not directly comparable to the AMBITION trial – both in terms of trial 
construct and the details reported, thus gives different but complimentary information.  
GRIPHON was a larger trial that included 170 PAH-SSc patients (15% of population)26, while 
the AMBITION trial included 118 PAH-SSc patients (24% of population). The mean age of the 
scleroderma population was marginally older (60 years old), while the overall population 
was younger in the GRIPHON trial 48yrs v 54.3yrs in the Ambition trial.  Time from diagnosis 
to trial inclusion in the AMBITION trial was short (median <1mo) and equivalent in both the 
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IPAH/HPAH and SSc-PAH populations, GRIPHON was a prevalent population study.  In the 
GRIPHON trial time from PAH diagnosis to enrolment was 1.6 years in the SSc population26, 
but 2.4 years in the overall population3 (> 60% of the whole population had 
IPAH/HPAH/drug or toxin associated PAH). Background therapy of PAH-PAH patients in the 
GRIPHON trial was almost identical to the whole population; 78% SSc v 80% whole 
population were on background therapy, 36% PAH-SSc patients were on background 
combination therapy, compared to 33% of the whole population.   
When comparing the studies, we are further limited by the lack of individual reporting of 
the details of the IPAH/HPAH population in the GRIPHON trial and the IPAH/HPAH 
population may have reached a more stable phase of the disease, given the likely longer 
time from diagnosis to enrolment.  The primary endpoint was different though similar, 
comprising disease progression or worsening of PAH that resulted in hospitalisation, 
initiation of parenteral prostanoid therapy or long-term oxygen therapy, need for lung 
transplantation or balloon atrial septostomy, or death from any cause). Disease progression 
was defined as a ≥15% decrease in 6-minute walk distance from baseline, confirmed by a 
second test on a different day, and worsening in WHO functional class (for patients in 
functional class II/III at baseline) or need for additional PAH therapy (for patients in 
functional class III/IV at baseline). The most important difference here is the absence of 
‘unsatisfactory long term clinical outcome’ as an endpoint. 
Overall, this was a very encouraging study that reached its key clinical trial endpoints.  In 
those randomised to placebo among the IPAH/HPAH/Drug group the primary endpoint 
occurred in 43%, compared to 49% in the PAH-SSc group26.  In the active treatment group 
the primary endpoint occurred in 28% of the IPAH/HPAH/Drug group compared to 32.5% 
with PAH-SSc. Again, suggesting that with aggressive management including 80% 
combination and 36% triple therapy PAH-SSc patients benefit at least as much as 
IPAH/HPAH patients and event rates approach those seen in the IPAH/HPAH group. 
In terms of secondary endpoints, we can only compare outcomes among PAH-SSc with the 
outcome in the whole population. With this limitation, as shown in Table 4 there is 
remarkable consistency between the effect of selexipag in all patients and those with 
systemic sclerosis. Death was an uncommon event as a primary endpoint, however numbers 
of events were not insignificant up to the end of study (i.e. including follow up of those that 
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had stopped treatment after meeting a primary endpoint).  Here a trend is noted – a 
possible reduction in mortality in the post-selexipag group for the whole population, with 
no impact on deaths in the SSc cohort.  It is however impossible to attribute a causative 
relationship in this setting, since the management decisions taken after cessation of trial 
treatment are unknown. 
Adverse events were common in the GRIPHON trial with over 95% reporting some adverse 
events. Serious adverse events were numerically more common in the SSc subpopulation, 
but the same trend toward reduced events in the active treatment sub group was seen.  
Discontinuation due to adverse events were also numerically more common in the SSc 
cohort (7.1% IPAH v 13.2% PAH-SSc among placebo patients and 14.3% IPAH v 19.5% PAH-
SSc in the active therapy arm), again with no trend toward a relative excess of SAE due to 
therapy when compared to the whole population. Thus, in a population with 80% on 
combination therapy and 36% on triple therapy – there is no evidence that escalation of 
treatment is disproportionately disadvantageous in the SSc cohort (Table 4). 
 
Concluding remarks: current approaches for PAH-SSc 
SSc PAH patients remain complex and we do not have all the answers yet.  What is clear is 
that in those with true PAH-SSc an aggressive approach with early combination therapy is 
the required standard of care.  This is in line with current evidence-based treatment 
recommendations27 and represents a meaningful advance in treatment for SSc in general 
that can be expected to improve disease outcome and survival.  Less clear is how we 
estimate the relative contributions of cardiac, pulmonary and musculoskeletal co-morbidity. 
Further in managing such patients we must always be cognisant of the role of the auto-
immune system, which drives the vasculopathy and can cause deterioration or crises 
entirely independent of the cardio-pulmonary axis. 
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Figure 1.   Meta-analysis of pulmonary hypertension trials including PAH-CTD and PAH-SSc  
Comparison of short term gains in six-minute walk distance suggest comparable absolute 
treatment effect for PAH-SSc but this does not reach statistical significance, most likely due 
to greater variability and small number of cases.  For clinical worsening, the reduction in 
hazard ration is comparable for PAH-SSc and iPAH. Modified from Rhee et al (ref 10).  CW – 
clinical worsening; Hosp – hospitalisation, Rx – treatment, Tx transplantation, RVF – right 
ventricular failure 
 
Figure 2.  A comprehensive diagnostic algorithm for PAH-SSc 
All cases of suspected PH should be evaluated and associated lung fibrosis or cardiac causes 
of PH excluded.  Features of other causes such as PVOD and CTEPH also require exclusion 
While the principle for the evaluation of SScPAH is identical to that of IPAH, the likelihood of 
co-existent lung or heart involvement is much greater. Some abnormality of the heart or 
lung is present in the majority of patients. The issue is not generally exclusion of lung or 
heart disease, but determining whether the abnormality observed is sufficient to explain the 
haemodynamic abnormality found. For lung disease < 20% volume of fibrosis or less than 5% 
emphysema is unlikely to cause precapillary PH in Systemic sclerosis patients. For heart 
disease, even minor abnormalities should cause suspicion that demonstration of a wedge of 
< 15 mmHg is not sufficient to make a diagnosis of precapillary PH, thus LVEDP and CMR 
should be considered. Finally, if more than a single CT feature of PVOD (septal lines, 
lymphadenopathy or centrilobular nodules) are identified, there is a significant risk of 
pulmonary oedema with advanced therapies.  
LVEF – left ventricular ejection fraction; LA – left atrium; MAPSE – mitral annular plane 
systolic elevation; LVEPD – left ventricular end diastolic pressure; CMR – cardiac magnetic 
resonance. 
 
Figure 3.  Comparison of IPAH groupings and connective tissue disease (CTD) populations.  
Forest plot summarising overall treatment effect on hazard ratio for event driven long term 
trials including combination PAH therapy in SSc.  For the licensed dose of macitentan and in 
selexipag and ambition study effect was similar fr the PAH-CTD and iPAH subjects.  The trials 
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had different primary end points, slightly different definitions of the IPAH groupings, 
different proportions of the various CTD populations and in the case of the ambition trial an 
incident population, so the trials should not be compared to each other, however 
presentation in a single Forest plot allows visual appreciation of the relative impact of 
different aggressiveness of the treatment regime with relative outcomes between the IPAH 
and CTD groups.  HR – hazard ratios for morbidity or mortality/ clinical failure outcomes 
relative to placebo groups. For each study, the IPAH group is the upper of the two hazard 
ratios shown. Numbers of patients followed by numbers with events is shown for the active 
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Compass-2 18 226 88 38 ? 100% v 0% 
Seraphin 4 
3mg & 10mg 
449 225 116 66 64% 
Ambition 1 279 187 118 17 100% v 0% 
Griphon 3 712 334 170 82 80% 










RFH registry16 Compera17 
Age (years) 58 61.8+11 63.9+10.5 63+11 67 (59.5-74) 
Sex (F %) 85 88.5 82 85 84 
FC I or II /III/IV 
(%) 
23/77/0 25/60/15 16/68/16 21/79 (III+IV) 14/72/14 
TLC 
(% pred) 
90 82.7+18.4 NR NR (FVC 94%) NR 
FEV1 
(% pred) 
86 73.4+16.4% NR NR NR 
mPAP 
(mm Hg) 
44 44.6+11.8 42+17 40+12 41+11 
PVR 
(dynes.sec.cm-5) 
670 9.6+5.3 715+597 607+417 697+385 
PCW (mm Hg) 8.5 9.1+3.5 NR 10+3 9.3+3.3 















19% 32% 0.51 
(0.31-
0.83) 





8% 18% 0.41 
(0.2–0.82) 





+52.5 +26.6   +40.9m +12.2m   
NTproBNP -71.2% -50% -42.5 
(-54.6;-
27) 






40% 28% 1.7 
(1.04-2.9) 
31% 29% 1.1 
(0.47-2.6) 
15% fall in 
6MWD 
24% 32%   31% 44%   
SAE rate 33% 38%   44% 49%   
AE resulting in 
discontinuation 
11% 10%   14% 13%   
 
  
Table 4    Summary of outcome data from the Griphon clinical trial 
 













to the end of treatment 
Number of patients (%) Number of patients (%) 





worsening of PAH 








Death from any cause 18 (3.1) 28 (4.9) 1 (1.1) 4 (5.2) 
Initiation of parenteral 
prostanoid therapy or 
long-term O2 therapy for 
worsening PAH 
13 (2.2) 10 (1.7) 5 (5.4) 2 (2.6) 
Need for lung 
transplantation or BAS 
for worsening of PAH 
2(0.3) 1 (0.2) 0 1 (1.3) 
Secondary endpoint of 
all-cause death up to the 
end of the study 
Number of patients (%) Number of patients (%) 

















IPAH CTD PAH SSC PAH
Rx group Placebo Treatment Effect
Clinical worsening
(excluding Seraphin post 18 wk)





CW = hosp for PAH; Rescue Rx; Lung Tx
Septostomy; RVF; Death
D = -4.2 p = ns






Figure 2. A comprehensive diagnostic algorithm for PAH-SSc
 
      Diagnostic Algorithm for SSc PAH 
Suspect PAH/PH 
Falling effort tolerance 
DETECT positive 
ESC Echo criteria for PH 
Cardiac Assessment 
LVEF < 55% or wall motion 
abnormality 
Significant valve disease 
LA > 20cm2/> 58ml 
Diastolic wall thickness > 
1.2cm 
EE’ > 15 or MAPSE < 10mm 
Troponin > 14pmol/l 
Lung assessment 
HRCT  
> 20% fibrosis and/or > 5% Emphysema 
>1 CT criteria for PVOD 
VQ scan  
consistent with CTED 
PFT 
FVC < 70%; FEV1 < 50%; DLCO < 25% 
And/ 
Suspect left heart contribution 
CMR heart 
If catheter: 
Left heart catheter including 
LVEDP 
Consider fluid challenge 
 
Suspect lung contribution/CTEPH 
Analyse serial PFT over preceding years 
– determine if lung disease stable while 
symptoms progressive 
If CTEPH – CTPA to assess operability 
Cardiac catheterisation 
Optimal hydration: free fluids before 
procedure;  





Progressive or advanced    
lung disease 
cannot be excluded 
Treat heart disease Treat lung disease 
Yes Yes 
No No 
Figure 3.  Comparison of IPAH groupings and connective tissue disease (CTD) populations. 
0 0.5 1 1.5 2
Favours active comparator Favours placebo
HR and CI 95%
